Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on October 17, 2025, covering the event date of October 15, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol SPRB. The filing is an emerging growth company report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of a director:
- Resignation: Bali Muralidhar, Ph.D., resigned as a member of the Board of Directors and the Compensation Committee.
- Effective Date: October 15, 2025 (immediate).
- Reason: The resignation is not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks, contingencies, or unusual items were disclosed in this report beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Dr. Muralidhar's immediate resignation.
- Confirm whether the Compensation Committee has appointed a replacement to maintain quorum and functionality.
- Review subsequent filings for any impact on corporate governance or strategic direction resulting from this leadership change.